Key result
The HeartMate II left ventricular assist device did not result in significant weight loss at 6 months in obese heart failure patients, whereas the HeartMate XVE did.
Why the study?
Does the HeartMate II left ventricular assist device improve weight loss in obese heart failure patients compared to the HeartMate XVE?
Cohort (n=22)
No
Does the HeartMate II left ventricular assist device improve weight loss in obese heart failure patients compared to the HeartMate XVE?
The newer generation continuous flow HeartMate II VAD does not induce significant weight loss at 6 months in obese heart failure patients, unlike the older HeartMate XVE.
Answers are grounded in this paper and cite their sources.
HeartMate II was not associated with weight loss in obese HF patients; leaves open whether device generation influences body weight.
BACKGROUND: The purpose of this study is to evaluate the effect on weight loss of the newer generation continuous flow HeartMate II™ left ventricular assist device (VAD) in obese heart failure (HF) patients. MATERIAL/METHODS: We retrospectively reviewed 3-year surgical data from a large heart transplant facility and identified obese patients with advanced heart failure who underwent successful implantation of either the HeartMate XVE(®) or the HeartMate II(®) VAD. For each patient weight and BMI at time of VAD implantation and at 6 months post-operatively were documented. Between group comparison was achieved with Student's T tests. RESULTS: We identified 14 patients who had received the HeartMate XVE™ and 8 who had received the HeartMate II™. At 6 months, patients who received a HeartMate XVE™ demonstrated a significant reduction in mean body weight (249.6 ± 35.4lbs vs. 217.4 ± 20.5 lbs; P<0.05), while patients who received the HeartMate II™ demonstrated no significant change in weight (234.5 ± 41.7 lbs vs. 234.7 ± 43.0lbs; P=0.3). CONCLUSIONS: The HeartMate XVE™ results in significant reductions in weight at 6 months in obese patients with heart failure while the HeartMate II does not. Further research is necessary to better understand the effects of VADs on weight loss in obese HF patients.
No takes yet. Share an insight, caveat, or question.
Thompson et al. (2011) conducted a cohort in obese heart failure (n=22). HeartMate II left ventricular assist device vs. HeartMate XVE left ventricular assist device was evaluated on weight loss at 6 months post-operatively. The HeartMate II left ventricular assist device did not result in significant weight loss at 6 months in obese heart failure patients, whereas the HeartMate XVE did.
Synapse has enriched 10 related papers. Consider them for comparative context: